Valuation: argenx SE

Capitalization 41.74B 49.13B 38.22B 36.09B 67.01B 4,631B 67.78B 453B 177B 2,223B 184B 180B 7,686B P/E ratio 2026 *
27.8x
P/E ratio 2027 * 21.7x
Enterprise value 37.14B 43.72B 34.01B 32.11B 59.62B 4,120B 60.31B 403B 157B 1,978B 164B 161B 6,839B EV / Sales 2026 *
7.29x
EV / Sales 2027 * 5.73x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * 0.17%
1 day+0.03%
1 week-1.90%
Current month+0.51%
1 month+0.12%
3 months-4.30%
6 months-9.90%
Current year-6.33%
1 week 665.8
Extreme 665.8
716.4
1 month 646
Extreme 646
721
Current year 568.4
Extreme 568.4
738
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 10.15
Extreme 10.15
810
Manager TitleAgeSince
Chief Executive Officer 47 05/05/2026
Director of Finance/CFO 56 31/05/2021
Chief Tech/Sci/R&D Officer - 31/12/2014
Director TitleAgeSince
Chairman 54 05/05/2026
Director/Board Member 76 12/05/2015
Director/Board Member 65 27/04/2016
Change 5d. change 1-year change 3-years change Capi.($)
+0.03%-1.90%+38.06%+84.10% 49.13B
+2.09%+1.58%+91.04%+67.41% 49.58B
-23.41%-22.98%+53.78%+441.24% 22.66B
-2.35%-10.08%+0.24%-14.21% 23.52B
-1.86%-5.50%+44.83%-31.10% 17.59B
-9.06%-5.93%+23.53%-41.99% 17B
-2.83%+4.85%+59.05%+199.44% 16.22B
-3.92%-20.08%-29.39%+690.32% 13.31B
-1.71%-2.99%+36.01% - 13.55B
-0.90%+3.38%+78.98%+74.58% 12.33B
Average -4.39%-4.54%+39.61%+163.31% 23.49B
Weighted average by Cap. -3.40%-3.67%+46.08%+132.03%

Financials

2026 *2027 *
Net sales 5.06B 5.96B 4.64B 4.38B 8.13B 562B 8.22B 54.96B 21.41B 270B 22.36B 21.89B 933B 6.19B 7.28B 5.67B 5.35B 9.93B 686B 10.05B 67.15B 26.17B 330B 27.32B 26.75B 1,139B
Net income 1.58B 1.87B 1.45B 1.37B 2.54B 176B 2.57B 17.2B 6.7B 84.4B 7B 6.85B 292B 2.07B 2.44B 1.89B 1.79B 3.32B 230B 3.36B 22.46B 8.75B 110B 9.14B 8.95B 381B
Net Debt -4.6B -5.41B -4.21B -3.98B -7.38B -510B -7.47B -49.92B -19.45B -245B -20.31B -19.89B -847B -6.65B -7.82B -6.09B -5.75B -10.67B -737B -10.8B -72.15B -28.11B -354B -29.35B -28.74B -1,224B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
08/05/26 671.40 +0.03% 14,424
07/05/26 671.20 -2.50% 110,846
06/05/26 688.40 +1.44% 90,590
05/05/26 678.60 -0.85% 84,716
04/05/26 684.40 +2.46% 108,231
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
671.20EUR
Average target price
844.81EUR
Spread / Average Target
+25.87%

Quarterly revenue - Rate of surprise